Showing 2161-2170 of 9592 results for "".
Special Report: COVID-19: Surgeons Support Front Lines, How to Cope
https://practicaldermatology.com/topics/practice-management/special-report-covid-19-surgeons-support-front-lines-how-to-cope/19757/The AAFPRS calls on surgeons to consider donating PPE and supplies like ventilators and beds, as nurses call for more preparation for COVID-19. Experts offer strategies for coping with the current environment and planning ahead. Although the AAD Annual Meeting has been cancelled, voting for new offiThe Neuroimmune Mechanisms Driving Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37136/Practical Dermatology Editorial Board member Todd Schlesinger, MD, a board-certified dermatologist and Mohs surgeon with Epiphany Dermatology in Charleston, South Carolina, discusses the neuroimmune mechanisms that drive prurigo nodularis and how they differ from those in chronic pruritus and atopicHow Reviews Impact Your Practice Today and Tomorrow
https://practicaldermatology.com/topics/practice-management/how-reviews-impact-your-practice-today-and-tomorrow/19892/Are you harnessing the power of patient reviews? It has never been more important to generate quality reviews from real people. In this video, Ekwa Marketing explores the factors that drive positive reviews. And the opportunities presented by this platform to grow loyalty and attract new patients.Build a Better Relationship with Your Dermatopathologist
https://practicaldermatology.com/topics/skin-cancer-photoprotection/build-a-better-relationship-with-your-dermatopathologist/18532/A strong relationship between the dermatologist and dermatopathologist is essential in achieving the best diagnosis for the patient. Abel Jarell, MD offers insights for helping your dermatopathologist work smarter for you and how to avoid potential pitfalls.First Cell-Based Gene Therapy for RDEB
https://practicaldermatology.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingWhat Should Dermatology PAs Look For in a Contract
https://practicaldermatology.com/series/pa-perspectives/what-should-dermatology-pas-look-contract/24164/In this video, Andrew Mastro, MS, PA-C, a board-certified physician assistant (PA) at the Illinois Dermatology Institute in Chicago, shares insights into what dermatology PAs should think about for their employment contracts (particularly when starting out at their first practice). Some of the topicFirst, Do No Harm
https://practicaldermatology.com/conferences/scale-2023/first-do-no-harm/20206/Joel L. Cohen, MD, and Mathew M. Avram, MD, JD, discuss why dermatologists should report any side effects to the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database.Lidocaine Shortage Update
https://practicaldermatology.com/conferences/scale-2023/lidocaine-shortage-update/20196/The current lidocaine and lidocaine with epinephrine shortage is affecting practices across the country. Joel L. Cohen, MD, and George Hruza, MD, weigh in on the shortage and potential solutions and how to minimize toxicity risks when mixing and matching different anesthetics.Tolerability of JAK Inhibitors Used in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/tolerability-of-jak-inhibitors-used-in-dermatology/20126/Although safety and tolerability are often intertwined, they are distinct considerations. Topical and oral JAKs used in dermatology today seem to offer good tolerability. Adelaide A. Hebert, MD and Matthew Zirwas, MD discuss potential side effects, management, and monitoring in pediatric and adult pClinical Conversations: Risks vs Benefits of JAK Inhibitors
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-risks-vs-benefits-of-jak-inhibitors/20108/Clinical data for JAK inhibitors show clear benefits for many patients. But these drugs are associated with certain risks and class warnings. Matt Zirwas, MD and Adelaide Hebert, MD describe how they weigh risks, educate patients, and optimize long-term management.